1088.20 -2.25 (-0.21%)
169.5K Volume
NSEJan 15, 2021 03:31 PM
The 23 reports from 8 analysts offering long term price targets for Alembic Pharmaceuticals Ltd. have an average target of 1120.86. The consensus estimate represents an upside of 3.00% from the last price of 1088.20.
Summary | Date | Stock | Broker | Price at Reco. | Target | Price at reco Change since reco(%) | Upside(%) | Type | Report | Discuss |
---|---|---|---|---|---|---|---|---|---|---|
2020-10-26 | Alembic Pharmaceutic.. + | KRChoksey | 963.20 | 1286.00 | 963.20 (12.98%) | 18.18 | Buy | Alembic Pharma
KRChoksey
Alembic pharma reported yet another outstanding quarterly numbers with 7%/21%/34% higher Revenue/EBITDA/PAT from our estimates. The beat was supported by strong growth in Azithromycin OSD along with the strong market share gain. Lagging therapies of Gastroenterology and Gynecology also reported significant improvement during the quarter. Geography wise, growth in revenue was led by the ROW market which grew by 84.1% YoY (14% of revenue, up 3.3% QoQ) due to continued recovery in the European businesses from supply chain related issues and API business which grew by 28.9% YoY (18% of revenue, flat QoQ). The...
| ||
2020-10-23 | Alembic Pharmaceutic.. + | Yes Securities | 973.75 | 1180.00 | 973.75 (11.75%) | 8.44 | Buy | |||
2020-10-23 | Alembic Pharmaceutic.. + | ICICI Securities Limited | 973.75 | 1170.00 | 973.75 (11.75%) | 7.52 | Buy | |||
2020-10-23 | Alembic Pharmaceutic.. + | Nirmal Bang Institutional | 973.75 | 1116.00 | 973.75 (11.75%) | Target met | Accumulate | |||
2020-10-22 | Alembic Pharmaceutic.. + | BOB Capital Markets Ltd. | 973.75 | 1180.00 | 973.75 (11.75%) | 8.44 | Buy | |||
2020-07-23 | Alembic Pharmaceutic.. + | Nirmal Bang Institutional | 980.20 | 883.00 | 980.20 (11.02%) | Target met | Accumulate | Alembic Pharmaceuticals- 1QFY21 Result Update- Strong API sales drive performance
Nirmal Bang Institutional
Team in the Asia Money poll 2020. Click Here Alembic Pharma's 1QFY21 revenue at Rs13,413mn grew by 11.1% QoQ and 41.4% YoY. Revenue was 7%/14.1% above our/consensus estimates, respectively. The outperformance was largely driven by strong growth in API and ex-US generic formulation sales. API sales grew by 70% QoQ and Azithromycin exports were an important contributor. For the full year, the growth rate in API sales would be in the range of 15-20%. US sales were up 3% QoQ and were led by an increase in famotidine prescriptions, which were partially offset by lower sales in febuxostat and sartan...
| ||
2020-07-23 | Alembic Pharmaceutic.. + | Karvy | 960.80 | 939.00 | 960.80 (13.26%) | Target met | Sell | |||
2020-07-23 | Alembic Pharmaceutic.. + | ICICI Securities Limited | 980.20 | 1140.00 | 980.20 (11.02%) | Target met | Buy | Alembic Pharmaceuticals
ICICI Securities Limited
Domestic sales comprise 31% of FY20 revenues with higher contribution from specialty (54% of domestic sales). However, despite having an established set-up, growth (FY16-20 CAGR of ~5%) has lagged the industry growth curve. Alembic is consciously focusing on this aspect by overhauling distribution channels (defocusing on trade generics). Overall, we expect...
| ||
2020-07-14 | Alembic Pharmaceutic.. + | Karvy | 949.50 | 927.00 | 949.50 (14.61%) | Target met | Sell | FY20: Key Takeaways
Karvy
Domestic Formulations A Mixed Bag: The domestic formulations industry grew by 9.7% during the quarter and 9.8% for the year. The last 15-20 days of the March quarter were an issue due to COVID-19 and lockdown. Digital marketing, video calling had replaced the traditional mode of personalvisits and marketing.
| ||
2020-07-05 | Alembic Pharmaceutic.. + | Motilal Oswal | 914.60 | 975.00 | 914.60 (18.98%) | Target met | Neutral | Huge capex cycle nears completion
Motilal Oswal
5 July 2020 ALPM delivered a 14% CAGR in US sales to USD280m (43% of sales) on account of 58 launches over FY1620. Particularly, in FY20, ALPM garnered 49% YoY growth, led by new launches (22) and partly by regulatory concerns witnessed by peers. On a high FY20 base, we expect a 10% CAGR in US sales to USD340m over FY20 22. ALPM would ramp up filings across new dosages (Ophthalmology, General Injectables, Oncology Injectables, and Oral Solids). The considerable share of revenue from new capex / product development would reflect in overall growth in US sales 2HFY22 onward; thus, it forms a marginal portion of the business trajectory over FY2022. ALPM delivered 13% YoY growth in 4QFY20, reflecting the benefit of the pre-buying of medicines (in anticipation of shortage due to COVID-19) and partly of renewed strategy. While efforts to improve sales growth have been on track, performance could be dented on account of the COVID-19-led slowdown.
| ||
2020-06-15 | Alembic Pharmaceutic.. + | Nirmal Bang Institutional | 889.95 | 835.00 | 889.95 (22.28%) | Target met | Accumulate | Alembic Pharmaceuticals- Initiating Coverage- Fairly valued - Await clarity on evolution of limited competition portfolio
Nirmal Bang Institutional
Fairly valued - Await clarity on evolution of limited competition portfolio ACCUMULATE We initiate coverage on Alembic Pharma Limited (APL) with a target price of Rs835 and recommend an Accumulate at CMP. APL was founded in 1907 having a legacy that dates back to over a century. The company business is split between domestic branded formulations (31%), international generics (54%) and APIs (15%). APL has grown from a domestic focused name to a global generics player. In FY20, generic formulation sales in the US emerged as the single largest segment - contributing 43% to FY20 revenue. Unlike peers, where the US business has below par profitability, APL's profitability is superior with its revenue per Rx figures in the US at almost 2 ...
| ||
2020-05-19 | Alembic Pharmaceutic.. + | Yes Securities | 870.30 | 1100.00 | 870.30 (25.04%) | Target met | Buy | Alembic Pharma
Yes Securities
of capex is monetized from next fiscal. In the current disruptive environment, we reckon stocks with high certainty of earnings would command a disproportionate investorinterestandwidepremiumtosectoraverages.WebelieveAlembicPharma fitsthebillasitforaysintooncoandgeneralinjectablesandimprovestherevenue mixin3years.ExpectUSbusinesstoclock20%cagrexSartansovernext4yearsto touch ~US$450mn in FY24E. Domestic business should rebound and our recovery case is premised on strong close to Q4 FY20 as well as positive management commentary.WeassumemoderationingrossmarginthoughEBIDTAshouldpickup...
| ||
2020-04-24 | Alembic Pharmaceutic.. + | Karvy | 743.50 | 806.00 | 743.50 (46.36%) | Target met | Hold | Alembic Pharmaceuticals Ltd
Karvy
The company's revenue from Domestic Formulations (DF)grew by 13% to Rs.3.4 bn. US revenues grew by 84% on YoY basis to Rs. 5.8 bn. This has been on account of supply constraints in the Sartan space in the US market coupled with new launches. ROW markets grew by 61% to Rs. 1320 mn. API business degrew by 31% to Rs. 1550 mn during Q4 FY20.
| ||
2020-04-24 | Alembic Pharmaceutic.. + | ICICI Securities Limited | 817.30 | 875.00 | 817.30 (33.15%) | Target met | Buy | Alembic Pharmaceuticals
ICICI Securities Limited
Domestic sales comprise 31% of FY20 revenues with higher contribution from specialty (54% of domestic sales). However, despite having an established set-up, growth (FY16-20 CAGR of ~5%) has lagged the industry growth curve. The company is consciously focusing on this aspect with focus on overhauling of distribution channels (defocusing on trade...
| ||
2020-04-24 | Alembic Pharmaceutic.. + | BOB Capital Markets Ltd. | 760.20 | 810.00 | 760.20 (43.15%) | Target met | Buy | |||
2020-04-23 | Alembic Pharmaceutic.. + | BOB Capital Markets Ltd. | 760.20 | 810.00 | 760.20 (43.15%) | Target met | Buy | |||
2020-04-23 | Alembic Pharmaceutic.. + | Motilal Oswal | 760.20 | 705.00 | 760.20 (43.15%) | Target met | Neutral | Good show in key geographies (US/India) drives earnings
Motilal Oswal
ALPM remains on track in terms of finishing its large capex project (~INR25b) to enhance new dosage offerings and increase capacity requirements in the US Generics segment. ALPMs 4QFY20 revenues came in at INR12.1b, up 30% YoY, led by International Formulations (+80% YoY), supported by growth in the US segment (48% of sales; +84% YoY to USD75m) and the Non-US segment (11% of sales; +63% YoY). The gross margin expanded 140bp YoY to 78% owing to a superior product led by improved operating leverage (employee cost down -120bp YoY/other expenses down 520bp YoY as % of sales, offset by higher R&D; expense of For FY20, revenue/EBITDA/Adj.PAT stood at INR46.1b/INR12b/INR8.3b, largely led by strong traction in US generic. The US base business from already-approved products is likely to witness a quarterly run rate of USD70m (v/s USD50m up to 3QFY20) going forward.
| ||
2020-04-20 | Alembic Pharmaceutic.. + | ICICI Securities Limited | 617.95 | 685.00 | 617.95 (76.10%) | Target met | Hold | Alembic Pharmaceuticals
ICICI Securities Limited
On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....
| ||
2020-01-24 | Alembic Pharmaceutic.. + | Karvy | 639.85 | 3.00 | 639.85 (70.07%) | -99.72 | Hold | |||
2020-01-23 | Alembic Pharmaceutic.. + | ICICI Securities Limited | 589.85 | 620.00 | 589.85 (84.49%) | Target met | Hold | Alembic Pharmaceuticals
ICICI Securities Limited
Specialty contribution in the domestic branded space increased to 63% in FY19 from 54% in FY14. However, despite having an established set up, growth (FY14-19 CAGR of 5%) has lagged the industry growth curve. The company is consciously focusing on this aspect with focus on overhauling of distribution channels (defocusing on trade generics). Overall, we expect...
| ||